NL-OMON39496尚未招募不适用
Dynamic FDG-PET/CT response during chemoradiation for NSCLC - PET response during chemoradiation of lung cancer
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Cytologically or histologically proven NSCLC
- •T2-4 N0-3 M0 disease (stage II or III, inoperable)
- •Scheduled for standard concurrent chemoradiation
- •Primary tumour minimal diameter 3 cm
- •Primary tumour SUVmax > 5 on routine diagnostic pre-treatment FDG PET/CT
- •WHO performance 0-1
- •Written informed consent according to GCP and national regulations
排除标准
- •Age < 18 years
- •Incapacitated subjects
- •Pregnant or lactating women
- •Diabetes Mellitus
- •Participation in dose escalation studies
- •Other neoplasms with metastases in the last 3 years
研究者
相似试验
已完成
不适用
PET Response During Chemoradiation of Lung CancerNSCLCNCT02315053The Netherlands Cancer Institute40
已完成
不适用
Dynamic study of FDG-PET/CTJPRN-UMIN000023983Tokushima University Hospital50
已完成
不适用
dynamic study of FDG-PET/CT and MET-PET/CT in evaluation of cervical lymph nodehead and neck cancerJPRN-UMIN000027466Tokushima University Hospital50
终止
1 期
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical CancerCervical CancerUterine Cervical CancerUterine Cervical NeoplasmsNCT02317302Washington University School of Medicine48
招募中
不适用
FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.Esophageal cancerJPRN-UMIN000002249Osaka Medical Center for Cancer and Cardiovascular Diseases30